Both Pfizer and GSK have shared preliminary data suggesting that their experimental vaccines can protect older adults and newborn infants from the virus.
In line with previous research, a new study in mice demonstrates that B cells can be engineered to ward off infections, this time against respiratory syncytial virus (RSV).
ADVERTISEMENT
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.